Aktien Sensor

Solventum partners with SprintRay to enhance digital dentistry capabilities, aiming to optimize workflows and drive innovation in the industry.

Solventum Corp is poised for significant growth as it capitalizes on the rapidly expanding Hospital Information Systems market, with Stifel maintaining a Buy rating on its stock.

Solventum Corp has reaffirmed its 2025 guidance and outlined a long-range plan through 2028, driven by growth prospects in the expanding Hospital Information Systems Market.

Solventum’s stock price has reached a 52-week high of $96.05 USD, driven by investor excitement over the company’s new Attest eBowie-Dick Test System.

Solventum Corp’s stock value has surged following its acquisition by Thermo Fisher, marking a major milestone in the company’s turnaround efforts.